SEROQUEL XR SUMMARY
SEROQUEL XR (quetiapine fumarate) is a psychotropic agent belonging to a chemical class, the dibenzothiazepine derivatives.
All doses and tablet strengths are expressed as milligrams of base, not as fumarate salt.
SEROQUEL XR is indicated for the treatment of schizophrenia.
The efficacy of SEROQUEL XR in schizophrenia was established in part, on the basis of extrapolation from the established effectiveness of SEROQUEL. In addition, the efficacy of SEROQUEL XR was demonstrated in 1 short-term (6-week) controlled trial of schizophrenic inpatients and outpatients [ see Clinical Studies ].
The effectiveness of SEROQUEL XR in long-term use, that is, for more than 6 weeks, has not been systematically evaluated in controlled trials. Therefore, the physician who elects to use SEROQUEL XR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient [ See Dosage And Administration ].
|
NEWS HIGHLIGHTSMedia Articles Related to Seroquel XR (Quetiapine)
Schizophrenia And Psychotic Syndromes
Source: Schizophrenia News From Medical News Today [2010.08.31]
Schizophrenia and related psychotic disorders are a chronic and often disabling condition. Despite modern treatment techniques they still present an enormous burden to the patients and their relatives and take a serious toll in terms of human suffering and societal expenditure...
Scientists Measure Gene Mutation Rate In Autism And Schizophrenia
Source: Autism News From Medical News Today [2010.08.30]
An international study led by University of Montreal scientists suggests family history may not be a good predictor of the presence of mutations predisposing to autism or schizophrenia. The findings show how new or de novo gene mutations - alterations of the cell's DNA - play a role in these devastating conditions...
Peaking At $6.3 Billion In 2011, Generic Erosion Of Antipsychotics Will Cause The Schizophrenia Drug Market To Decline To $5.2 Billion In 2019
Source: Schizophrenia News From Medical News Today [2010.08.16]
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, after peaking at $6.3 billion in 2011, the schizophrenia drug market will decline to $5.2 billion in 2019, owing to the loss of patent protection for most atypical antipsychotics on the market...
Special Issue Of Current Directions In Psychological Science Focuses On Schizophrenia Research
Source: Schizophrenia News From Medical News Today [2010.08.16]
It has been nearly a century since the term "schizophrenia" was first used to describe what was then considered a hopeless and incurable disorder of thought and emotion. Schizophrenia is still baffling to both scientists and the general public, but it is no longer considered hopeless...
Immune Responses During Pregnancy Linked To Schizophrenia Among Offspring
Source: Schizophrenia News From Medical News Today [2010.08.13]
Infections like the flu are common occurrences during pregnancy, and research has shown that children born to mothers who suffered from flu, viruses and other infections during pregnancy have about a 1.5 to 7 times increased risk for schizophrenia. A new study out of Temple University examines what's behind that link...
Published Studies Related to Seroquel XR (Quetiapine)
Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. [2009.08.20]
The efficacy and tolerability of extended-release quetiapine fumarate (quetiapine XR) once-daily monotherapy in generalized anxiety disorder (GAD) was assessed. This multicentre, double-blind, randomized, placebo- and active-controlled, phase III trial consisted of a 1- to 4-wk enrolment/wash-out period and a 10-wk (8-wk active treatment, 2-wk post-treatment drug-discontinuation) study period; 873 patients were randomized to 50 mg or 150 mg quetiapine XR, 20 mg paroxetine, or placebo...
A double-blind, placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder. [2009.08]
CONCLUSIONS: The results suggest that quetiapine monotherapy is no more effective than placebo for the treatment of depression in adolescents with bipolar disorder. However, limitations of the study, including the high placebo response rate, may have contributed to our findings and should be considered in the design of future investigations of pharmacological interventions for this population.
Quetiapine augments the effect of citalopram in non-refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled study of 76 patients. [2009.07]
CONCLUSIONS: The combination of quetiapine and citalopram was more effective than citalopram alone in reducing OCD symptoms in treatment-naive or medication-free OCD patients. TRIAL REGISTRATION: www.trialregister.nl Identifier NTR116.
Olanzapine compared to quetiapine in adolescents with a first psychotic episode. [2009.07]
CONCLUSION: Olanzapine and quetiapine reduced psychotic symptoms in this adolescent sample. Patients on olanzapine gained significantly more weight. Side effects with both drugs seemed to be more prevalent than those reported in adult studies.
Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study. [2009.06]
CONCLUSION: In patients with MDD, quetiapine XR monotherapy (50/150/300 mg/day) is effective in reducing depressive symptoms, with improvement from Day 4 onwards. Safety and tolerability were consistent with the known profile of quetiapine.
Clinical Trials Related to Seroquel XR (Quetiapine)
Seroquel Extended Release (XR) for the Management of Borderline Personality Disorder (BPD) [Recruiting]
The Primary objective of this study is to evaluate Seroquel XR in the treatment of BPD. As
in many initial RCTs, the study will be of relatively short duration - 8 weeks - to assess
effectiveness and safety while maximizing retention. The specific aim is to determine if
Seroquel XR is superior to placebo. The primary outcome measure will be a statistically
significant difference between Seroquel XR compared to placebo on the ZAN-BPD, an objective
rating scale that addresses the severity of DSM-IV symptoms of the illness. As there is the
recent development of an extended release form of Seroquel (Seroquel XR) (Schulz et al.
2007), the new compound may offer several advantages in this study. Therefore, the
hypothesis of this study is that both doses of Seroquel XR (see below) will be superior to
placebo in an 8-week randomized trial as assessed by the ZAN-BPD.
To achieve the Primary Objective of this study, two doses of Seroquel XR will be tested -
150 mg/d and 300 mg/d. Thus, the study will be able to assess the effect of Seroquel XR
compared to placebo and to explore a dose effect.
Positron Emission Tomography (PET) Study With [11C]Raclopride to Determine Central D2 Dopamine Occupancy of SEROQUEL [Recruiting]
The aim of this study is to relate pharmacokinetics of two different formulations of
quetiapine to PET measured receptor occupancy in the brains of healthy subjects.
Efficacy of Seroquel Versus Seroquel With SSRI For Treatment of Depressive Disorder With Psychotic Features [Recruiting]
The purpose of this study is to compare the efficacy and tolerability of Seroquel
monotherapy for the treatment of Major Depression with Psychotic features with Seroquel plus
Selective Seratonin Reuptake Inhibitor.
High Dose of Quetiapine in Treating Subjects With Treatment Refractory Schizophrenia or Schizoaffective Disorder [Recruiting]
This study will investigate the safety and efficacy of quetiapine in sub-optimally
responding patients with DSM-IV schizophrenia using a double blind, randomized 12-week trial
comparing oral doses of 1200 mg/d to 600 mg/d of quetiapine.
Nis Register Study Comparing Seroquel and Seroquel Prolong [Recruiting]
The general aim of this non interventional study is to clarify what are the current clinical
treatment practices of Quetiapine Immediate Release and Quetiapine Extended Release. The
primary objectives of the study are: 1. To collect information on the used Quetiapine
Immediate Release or Quetiapine Extended Release medication 2. To collect information on
duration and number of hospitalisation days 3. Change of GAF points
|
